Showing results (211-220 of 230) with videos related to
Sort By:
Pageof 23
European Radiology|February 22, 2023
MRI assessment of rectal cancer response to neoadjuvant therapy: a multireader studyJonathan B Yuval, Sujata Patil, Natalie Gangai, et al.Diseases of the Colon and Rectum|September 8, 2018
Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II TrialMichael R Marco, Lihong Zhou, Sujata Patil, et al.Breast Cancer Research and Treatment|August 20, 2022
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility studyElaine M Walsh, Ayca Gucalp, Sujata Patil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell CarcinomaMartin H Voss, Ana M Molina, Ying-Bei Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.Clinical Breast Cancer|October 12, 2015
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast CancerNeil M Iyengar, Monica N Fornier, Steven M Sugarman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerAyca Gucalp, Sara Tolaney, Steven J Isakoff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.Cancer Immunology Research|September 3, 2016
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after ImmunotherapyDavid B Page, Jianda Yuan, David Redmond, et al.JAMA Network Open|January 9, 2024
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical TrialHannah M Thompson, Dana M Omer, Sabrina Lin, et al.Pageof 23